Journal of Clinical Epidemiology
Volume 63, Issue 10 , Pages 1110-1117 , October 2010

The likelihood of participation in clinical trials can be measured: the Clinical Research Involvement Scales

  • Paula M. Frew

      Affiliations

    • Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA
    • Emory Center for AIDS Research, Atlanta, GA, USA
    • The Hope Clinic of the Emory Vaccine Center, Decatur, GA, USA
    • Department of Behavioral Sciences and Health Education and the Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA
    • Corresponding Author InformationCorresponding author. The Department of Medicine, Division of Infectious Disease, The Hope Clinic of the Emory Vaccine Center, 603 Church Street, Decatur, GA 30030, USA. Tel.: 404-712-8546; fax: 404-712-9017.
    • ,
  • Su-I. Hou

      Affiliations

    • Department of Health Promotion and Behavior, College of Public Health, The University of Georgia, Athens, GA, USA
    • ,
  • Marsha Davis

      Affiliations

    • Department of Health Promotion and Behavior, College of Public Health, The University of Georgia, Athens, GA, USA
    • ,
  • Kayshin Chan

      Affiliations

    • The Hope Clinic of the Emory Vaccine Center, Decatur, GA, USA
    • ,
  • Takeia Horton

      Affiliations

    • The Hope Clinic of the Emory Vaccine Center, Decatur, GA, USA
    • ,
  • Justin Shuster

      Affiliations

    • The Hope Clinic of the Emory Vaccine Center, Decatur, GA, USA
    • ,
  • Brooke Hixson

      Affiliations

    • The Hope Clinic of the Emory Vaccine Center, Decatur, GA, USA
    • ,
  • Carlos del Rio

      Affiliations

    • Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA
    • Emory Center for AIDS Research, Atlanta, GA, USA
    • The Hope Clinic of the Emory Vaccine Center, Decatur, GA, USA
    • Department of Behavioral Sciences and Health Education and the Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA

,Accepted 20 December 2009.

References 

  1. Nash D. Issuing an EDICT. Pharm Ther. 2007;32:638–642
  2. Carter RE, Sonne SC, Brady KT. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study. BMC Med Res Methodol. 2005;5:1–5
  3. Simon V. Wanted: women in clinical trials. Science. 2005;308:1517
  4. Seto B. History of medical ethics and perspectives on disparities in minority recruitment and involvement in health research. Am J Med Sci. 2001;322:246–250
  5. Comis RL, Miller JD, Aldige CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol. 2003;21:830–835
  6. Murthy V, Krumholz H, Gross C. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–2726
  7. Curbow B, Fogarty LA, McDonnell KA, Chill J, Scott LB. The role of physician characteristics in clinical trial acceptance: testing pathways of influence. J Health Commun. 2006;11:199–218
  8. Wendler D, Kington R, Madans J, Wye GV, Christ-Schmidt H, Pratt LA, et al. Are racial and ethnic minorities less willing to participate in health research?. PLoS Med. 2006;3:e19
  9. Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Control Clin Trials. 1997;18:328–352
  10. Wood A, Grady C, Emanuel EJ. The crisis in human participants research: identifying the problems and proposing solutions. Available at http://www.bioethics.gov/emanuelpaper.html
  11. Opar A. New schemes aim to boost minority participation in research. Nat Med. 2007;13:764–765
  12. National Institutes of Health . NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Bethesda, MD: National Institutes of Health; 1994;
  13. Wermeling D, Selwitz A. Current issues surrounding women and minorities in drug trials. Ann Pharmacother. 1993;27:904–911
  14. Baird K. The new NIH and FDA medical research policies: targeting gender, promoting justice. J Health Polit Policy Law. 1999;24:531
  15. In:  Haynes M,  Smedley B editor. The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington, D.C.: National Academy Press; 1999;
  16. Katz RV, Kegeles SS, Kressin NR, Green BL, Wang MQ, James SA, et al. The Tuskegee legacy project: willingness of minorities to participate in biomedical research. J Health Care Poor Underserved. 2006;17:698–715
  17. Sengupta S, Strauss RP, DeVellis R, Quinn SC, DeVellis B, Ware WB. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr. 2000;24:275–284
  18. Frew PM, Archibald M, Martinez N, del Rio C, Mulligan M. Promoting HIV vaccine research in the African American community: does the theory of reasoned action explain potential outcomes of involvement?. Challenge J Morehouse Res Institute. 2008;13:61–97
  19. Smith YR, Johnson AM, Newman LA, Greene A, Johnson TRB, Rogers JL. Perceptions of clinical research participation among African American women. J Women's Health. 2007;16:423–505
  20. Gamble V. Under the shadow of Tuskegee: African Americans and health care. Am J Public Health. 1997;87:1773–1778
  21. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med. 1999;14:537–546
  22. Bagozzi RP, Lee K, Van Loo MF. Decisions to donate bone marrow: the role of attitudes and subjective norms across cultures. Psychol Health. 2001;16:29–56
  23. Davis C, Randhawa G. The influence of religion on organ donation and transplantation among the Black Caribbean and Black African population—a pilot study in the United Kingdom. Ethn Dis. 2006;16:281–285
  24. Shavers-Hornaday VL, Lynch CF, Burmeister LF, Torner JC. Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health. 1997;2:31–45
  25. Khaliq W, Gross M, Thyagarajan B, Jones-Webb R. What motivates minorities to participate in research?. Minn Med. 2003;86:39–42
  26. Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst. 1995;87:1747–1759
  27. Frew PM, del Rio C, Clifton S, Archibald M, Hormes J, Mulligan MJ. Factors influencing HIV vaccine community engagement in the urban South. J Community Health. 2008;33:259–269
  28. Gorelick PB, Richardson D, Hudson E, Perry C, Robinson D, Brown N, et al. Establishing a community network for recruitment of African Americans into a clinical trial. The African-American antiplatelet stroke prevention study (AAASPS) experience. J Natl Med Assoc. 1996;88:701–704
  29. BeLue R, Taylor-Richardson KD, Lin J, Rivera AT, Grandison D. African Americans and participation in clinical trials: differences in beliefs and attitudes by gender. Contemp Clin Trials. 2006;27:498–505
  30. Frew PM, del Rio C, Lu L, Clifton S, Mulligan M. Understanding differences in enrollment in a Phase IIb HIV vaccine trial among high-risk populations. J Acquir Immune Defic Syndr. 2009;50:314–319
  31. Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, et al. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep. 2005;120:543–548
  32. Muhib F, Lin L, Stueve A, Miller R, Ford W, Johnson W, et al. A venue-based method for sampling hard-to-reach populations. Public Health Rep. 2001;116:216–222
  33. Frew PM, Crosby RA, Salazar LF, Gallinot L, Bryant LO, Holtgrave DR. Acceptance of an HIV/AIDS vaccine among minority women. J Natl Med Assoc. 2008;100:802–813
  34. Fuchs J, Durham M, McLellan-Lemal E, Vittinghoff E, Colfax G, Gurwith M, et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2007;47:1–7
  35. Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of Enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604–612
  36. Koblin BA, Holte S, Lenderking B, Heagerty P. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. J Acquir Immune Defic Syndr. 2000;24:451–457
  37. Priddy FH, Cheng AC, Salazar LF, Frew PM. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. Int J STD AIDS. 2006;17:99–102
  38. Crosby RA, Holtgrave DR, Bryant L, Frew PM. Factors associated with the acceptance of an AIDS vaccine: an exploratory study. Prev Med. 2004;39:804–808
  39. Salazar LF, Holtgrave DR, Crosby RA, Peterson J, Frew PM. Issues related to gay and bisexual men's acceptance of a future AIDS vaccine. Int J STDs AIDS. 2005;16:546–548
  40. Mills E, Wilson K, Rachlis B, Griffith L, Wu P, Guyatt G, et al. Barriers to participation in HIV drug trials: a systematic review. Lancet. 2006;6:32–38
  41. Ajzen I, Fishbein M. Understanding attitudes and predicting behavior. Englewood Cliffs, NJ: Prentice-Hall; 1980;
  42. Fishbein M, Ajzen I. Belief, attitude, intention, and behavior. Menlo Park, CA: Addison-Wesley; 1975;
  43. Meyers LS, Gamst G, Guarino AJ. Applied multivariate research: design and interpretation. Thousand Oaks, CA: Sage Publications; 2006;
  44. Allen M, Liang T, Salvia T, Tjugum B, Gulakowski R, Murguia M. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr. 2005;40:617–624
  45. Gregory JR, McNaughton L. Brand logic: a business case for communications. J Adv Res. 2004;44:232–236
  46. Miller S, Berry L. Brand Salience Versus Brand Image: Two Theories of Advertising Effectiveness. J Advert Res. 1998;38:77–83
  47. Mangini MK. Branding 101: It's time for healthcare to embrace this marketing mainstay. Marketing Health Serv. 2002;22:20–23
  48. Moran WT. Brand presence and the perceptual frame. J Adv Res. 1990;30:9–15
  49. Zaichkowsky JL. Measuring the involvement construct. J Consumer Res. 1985;12:341–352
  50. Shinn E, Basen-Engquist K, Le T, Hansis-Diarte A, Bostic D, Martinez-Cross J, et al. Distress after an abnormal pap smear result: scale development and psychometric validation. Prev Med. 2004;39:404–412
  51. Alexander M, Berger W, Buchholz P, Walt J, Burk C, Lee J, et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes. 2005;3:1–11
  52. Chang M-W, Brown R, Nizke S. Scale development: factors affecting diet, exercise, and stress management (FADESM). BMC Public Health. 2008;8:1–7
  53. Hou S-I, Luh WM. The structure of a web-based HIV testing belief inventory (wHITBI) for college students: the evidence of construct validation. Med Inform Internet Med. 2007;32:83–92
  54. Brown TA. Confirmatory factor analysis for applied research. 1st edition. New York, NY: Guilford Press; 2006;
  55. Knight GP, Virdin LM, Ocampo KA, Roosa M. An examination of the cross-ethnic equivalence of measures of negative life events and the mental health among Hispanic and Anglo American children. Am J Community Psychol. 1994;22:767–783
  56. National Cancer Institute . Clear & simple: developing effective print materials for low-literate readers. Available at http://www.nci.nih.gov/cancerinformation/clearandsimple2003;Accessed January 21, 2009
  57. Kline RB. Principles and practice of structural equation modeling. 2nd edition.. New York, NY: Guilford Press; 2005;

 Sources of support: Partial support was provided by the Emory Center for AIDS Research (P30 AI050409), the Emory Vaccine Center (U19 AI057266), and the Emory HIV/AIDS Clinical Trials Unit (U01 AI069418).

PII: S0895-4356(09)00387-4

doi: 10.1016/j.jclinepi.2009.12.002

Journal of Clinical Epidemiology
Volume 63, Issue 10 , Pages 1110-1117 , October 2010

Article Tools